Ticagrelor is a PO drug which inhibits platelet aggregation. In combination with aspirin it is more effective than clopidogrel + aspirin at reducing the endpoint of MI or death from vascular events.
It will be started by secondary care and continued by cardiologists, so we shouldn’t really have to initiate it.
It will be started in patients who’ve had a STEMI where primary percutaneous coronary intervention (PCI) is considered and also in patients with a NSTEMI who have certain other risk factors.